Elevated activity of cyclin-dependent kinase 6 in human squamous cell carcinoma lines

Cell Growth and Differentiation

Volumn 8, Issue 4, 1997, Pages 361-370

  Timmermann, Stefanie ^a   Hinds, Philip W ^a   Münger, Karl ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; RETINOBLASTOMA PROTEIN;

ARTICLE; CANCER INHIBITION; CARCINOMA CELL; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; CARRIER PROTEINS; CELL CYCLE; CELL CYCLE PROTEINS; CYCLIN D1; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE 6; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P18; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLIN-DEPENDENT KINASES; CYCLINS; ENZYME INHIBITORS; EXONS; G1 PHASE; GENES, TUMOR SUPPRESSOR; GLUTATHIONE TRANSFERASE; HUMANS; MOUTH NEOPLASMS; ONCOGENE PROTEINS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 0030916439     PISSN: 10449523     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Vokes, E. E., Weichselbaum, R. R., Lippman, S. M., and Hong, W. K. Head and neck cancer. N. Engl. J. Med., 328: 184-194, 1993.
2. Fernandez-Martinez, J. A., Ruiz-Avila, I., Bravo, M., Ramos, M. C., Martinez-Lara, I., Urquia, M., and Gonzalez-Moles, M. A. Some histopathological and clinical correlations in oral squamous cell carcinoma. Bull. Group. Int. Rech. Sci. Stomatol. Odontol., 38: 11-15, 1995.
3. Field, J. K., Zoumpourlis, V., Spandidos, D. A., and Jones, A. S. p53 expression and mutations in squamous cell carcinomas of the head and neck: expression correlates with the patients' use of tobacco and alcohol. Cancer Detect. Prev., 18: 197-208, 1994.
4. Yeudall, W. A. Human papillomaviruses and oral neoplasia. Eur. J. Cancer, 28B: 61-66, 1992.
5. Field, J. K. Oncogenes and tumour-suppressor genes in squamous cell carcinoma of the head and neck. Eur. J. Cancer B Oral Oncol., 28B: 67-76, 1992.
6. Brachman, D. G., Graves, D., Vokes, E., Beckett, M., Haraf, D., Montag, A., Dunphy, E., Mick, R., Yandell, D., and Weichselbaum, R. R. Occurrence of p53 gene deletions and human papillomavirus infection in human head and neck cancer. Cancer Res., 52: 4832-4836, 1992.
7. Burns, J. E., Baird, M. C., Clark, L. J., Burns, P. A., Edington, E., Chapman, C., Mitchell, R., Robertson, G., Soutar, D., and Parkinson, E. K. Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines. Br. J. Cancer, 67: 1274-1284, 1993.
8. Caamano, J., Zhang, S. Y., Rosvold, E. A., Bauer, B., and Klein-Szanto, A. J. P. p53 alterations in human squamous cell carcinomas and carcinoma cell lines. Am. J. Pathol., 142: 1131-1139, 1993.
9. Kim, M. S., Li, S., Bertolami, C. N., Cherrick, H. M., and Park, N. State of p53, RB and DCC tumor suppressor genes in human oral cancer cell lines. Anticancer Res., 13: 1405-1414, 1993.
10. Largey, J. S., Meltzer, S. J., Sauk, J. J., Hebert, C. A., and Archibald, D. W. Loss of heterozygosity involving the APC gene in oral squamous cell carcinomas. Oral Surg. Oral Med. Oral Pathol., 77: 260-263, 1994.
11. Uzawa, K., Yoshida, H., Suzuki, H., Tanzawa, H., Shimazaki, J., Seino, S., and Sato, K. Abnormalities of the adenomatous polyposis coli gene in human oral squamous-cell carcinoma. Int. J. Cancer, 58: 814-817, 1994.
12. Todd, R., McBride, J., Tsuji, T., Donoff, R. B., Nagai, M., Chou, M. Y., Chiang, T., and Wong, D. T. W. Deleted in oral cancer (doc-1), a novel oral tumor suppressor gene. FASEB J., 9: 1362-1370, 1995.
13. Horowitz, J. M., Park, S-H., Bogenmann, E., Cheng, J-C., Yandell, D. W., Kaye, F., Minna, J. D., Dryja, T., and Weinberg, R. A. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumors. Proc. Natl. Acad. Sci. USA, 87: 2775-2779, 1990.
14. Lee, E. Y., To, H., Shew, J. Y., Bookstein, R., Scully, P., and Lee, W. H. Inactivation of the retinoblastoma susceptibility gene in human breast cancers. Science (Washington DC), 241: 218-221, 1988.
15. Yoo, G. H., Xu, H. J., Brennan, J. A., Westra, W., Hruban, R. H., Koch, W., Benedict, W. F., and Sidransky, D. Infrequent inactivation of the retinoblastoma gene despite frequent loss of chromosome 13q in head and neck squamous cell carcinoma. Cancer Res., 54: 4603-4606, 1994.
16. Buchkovich, K., Duffy, L. A., and Harlow, E. The retinoblastoma protein is phosphorylated during specific phases of the cell cycle. Cell, 58: 1097-1105, 1989.
17. Chen, P-L., Scully, P., Shew, J-Y., Wang, J. Y. J., and Lee, W-H. Phosphorylation of the retinoblastoma gene product is modulated during the cell cycle and cellular differentiation. Cell, 58: 1193-1198, 1989.
18. DeCaprio, J. A., Ludlow, J. W., Lynch, D., Furukawa, Y., Griffin, J., Piwnica-Worms, H., Huang, C. M., and Livingston, D. M. The product of the retinoblastoma susceptibility gene has properties of a cell cycle regulatory element. Cell, 58: 1085-1095, 1989.
19. DeCaprio, J. A., Furukawa, Y., Ajchenbaum, F., Griffin, J. D., and Livingston, D. M. The retinoblastoma-susceptibility gene product becomes phosphorylated in multiple stages during cell cycle entry and progression. Proc. Natl. Acad. Sci. USA, 89: 1795-1798, 1992.
20. Ludlow, J. W., Shon, J., Pipas, J. M., Livingston, D. M., and DeCaprio, J. A. The retinoblastoma susceptibility gene product undergoes cell cycle-dependent dephosphorylation and binding to and release from SV40 large T. Cell, 60: 387-396, 1990.
21. Matsushime, H., Quelle, D. E., Shurtleff, S. A., Shibuya, M., Sherr, C. J., and Kato, J. Y. D-type cyclin-dependent kinase activity in mammalian cells. Mol. Cell. Biol., 14: 2066-2076, 1994.
22. Meyerson, M., and Harlow, E. Identification of G(1) kinase activity for cdk6, a novel cyclin D partner. Mol. Cell. Biol., 14: 2077-2086, 1994.
23. Kato, J., Matsushime, H., Hiebert, S. W., Ewen, M. E., and Sherr, C. J. Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev., 7: 331-342, 1993.
24. Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J-Y., Bar-Sagi, D., Roussel, M. F., and Sherr, C. J. Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts. Genes Dev., 7: 1559-1571, 1993.
25. Hunter, T., and Pines, J. Cyclins and Cancer II: cyclin D and cdk inhibitors come of age. Cell, 79: 573-582, 1994.
26. Eldeiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., and Vogelstein, B. WAF1, a potential mediator of p53 tumor suppression. Cell, 75: 817-825, 1993.
27. Harper, J. W., Adami, G. R., Wei, N., Keyomarsi, K., and Elledge, S. J. The p21 CDK-interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell, 75: 805-816, 1993.
28. Xiong, Y., Hannon, G. J., Zhang, H., Casso, D., Kobayashi, R., and Beach, D. p21 is a universal inhibitor of cyclin kinases. Nature (Lond.), 366: 701-704, 1993.
29. Polyak, K., Lee, M. H., Erdjument-Bromage, H., Koff, A., Roberts, J. M., Tempst, P., and Massagué, J. Cloning of p27(Kip1), a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. Cell, 78: 59-66, 1994.
30. Matsuoka, S., Edwards, M. C., Bai, C., Parker, S., Zhang, P., Baldini, A., Harper, J. W., and Elledge, S. J. p57 KIP2, a structurally distinct member of the p21 CIP1 cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9: 650-662, 1995.
31. Hannon, G. J., and Beach, D. p15(INK4B) is a potential effector of TGF-β-induced cell cycle arrest. Nature (Lond.), 371: 257-261, 1994.
32. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin-D/CDK4. Nature (Lond.), 366: 704-707, 1993.
33. Guan, K-L., Jenkins, C. W., Li, Y., Nichols, M. A., Wu, X., O'Keefe, C. L., Matera, A. G., and Xiong, Y. Growth suppression by p18, a p16INK4/ MTS1 and p14INK4B/MTS2-related cdk6 inhibitor, correlates with wild-type pRB function. Genes Dev., 8: 2939-2952, 1994.
34. Chan, F. K. M., Zhang, J., Cheng, L., Shapiro, D. N., and Winoto, A. Identification of human and mouse p19, a novel cdk4 and cdk6 inhibitor with homology to p16INK4. Mol. Cell. Biol., 15: 2682-2688, 1995.
35. Zhang, H., Hannon, G. J., and Beach, D. p21-containing cyclin kinases exist in both active and inactive states. Genes Dev., 8:1750-1758, 1994.
36. Sherr, C. J. G1 phase progression: cycling on cue. Cell, 79: 551-555, 1994.
37. Bates, S., Parry, D., Bonetta, L., Vousden, K., Dickson, C., and Peters, G. Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene, 9: 1633-1640, 1994.
38. He, J., Olson, J. J., and James, C. D. Lack of p16INK4 or retinoblastoma protein (pRB), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res., 55: 4833-4836, 1995.
39. Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W., and Kaye, F. J. Absence of p16(INK4) protein is restricted to the subset of lung cancer lines that retains wildtype RB. Oncogene, 9: 3375-3378, 1994.
40. Wölfel, T., Hauer, M., Scheider, J., Serrano, M., Wölfel, C., Klehmann-Heib, E., DePlaen, E., Hankeln, K-H., Meier zum Büschenfelde, K-H., and Beach, D. A p16ink4a-insensitive cdk4 mutant targeted by cytolytic T-lymphocytes in a human melanoma. Science (Washington DC), 269: 1281-1284, 1995.
41. Lee, N. K., Ye, Y. W., Chen, J., Li, X., Waber, P. G., and Nisen, P. D. p53, retinoblastoma, and human papillomavirus in squamous cell carcinoma and adjacent normal mucosa of the upper aerodigestive tract. Arch. Otolaryngol. Head Neck Surg., 119: 1125-1131, 1993.
42. Templeton, D. J., Park, S. H., Lanier, L., and Weinberg, R. A. Nonfunctional mutants of the retinoblastoma protein are characterized by defects in phosphorylation, viral oncoprotein association, and nuclear tethering. Proc. Natl. Acad. Sci. USA, 88: 3033-3037, 1991.
43. Ishikawa, J., Xu, H-J., Hu, S-X., Yandell, D. W., Maeda, S., Kamidono, S., Benedict, W. F., and Takahashi, R. Inactivation of the retinoblastoma gene on human bladder and renal cell carcinomas. Cancer Res., 51: 5736-5743, 1991.
44. Kaye, F. J., Kratzke, R. A., Gerster, J. L., and Horowitz, J. M. A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding. Proc. Natl. Acad. Sci. USA, 87: 6922-6926, 1990.
45. Lee, E. Y-H. P., Bookstein, R., Young, L-J., Lin, C-J., Rosenfeld, M. G., and Lee, W-H. Molecular mechanism of retinoblastoma gene inactivation in retinoblastoma cell line Y79. Proc. Natl. Acad. Sci. USA, 85: 6017-6021, 1988.
46. Scheffner, M., Münger, K., Byrne, J. C., and Howley, P. M. The state of the p53 and retinoblastoma genes in human cervical carcinoma cell lines. Proc. Natl. Acad. Sci. USA, 88: 5523-5527, 1991.
47. Welch, P. J., and Wang, J. Y. J. A C-terminal protein-binding domain in the retinoblastoma protein regulates nuclear c-abl tyrosine kinase in the cell cycle. Cell, 75: 779-790, 1993.
48. Shew, J-Y., Lin, B. T., Chen, P. L., Tseng, B. Y., Yang, F. T., and Lee, W-H. C-terminal truncation of the retinoblastoma gene product leads to functional inactivation. Proc. Natl. Acad. Sci. USA, 87: 6-10, 1990.
49. Callender, T., El-Naggar, A. K., Lee, M. S., Frankenthaler, R., Luna, M. A., and Batsakis. J. G. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer (Phila.), 74: 152-158, 1994.
50. Lucas, J. M., Mountain, R. E., Gramza, A. W., Schuller, D. E., Wilkie, N. M., and Lang, J. C. Expression of cyclin D1 in squamous cell carcinomas of the head and neck. Int. J. Oncol., 5: 469-472, 1994.
51. Quelle, D. E., Ashmun, R. A., Hannon, G. J., Rehberger, P. A., Trono, D., Richter, K. H., Walker, C., Beach, D., Sherr, C. J., and Serrano, M. Cloning and characterization of murine p16 INK4a and p15 INK4b genes. Oncogene, 11: 635-645, 1995.
52. Lapointe, J., Lachance, Y., Labrie, Y., and Labrie, C. A p18 mutant defective in cdk6 binding in human breast cancer cells. Cancer Res., 56: 4586-4589, 1996.
53. Zariwala, M., Liu, E., and Xiong, Y. Mutational analysis of the p16 family cyclin-dependent kinase inhibitors p15INK4b and p18INK4c in tumor-derived cell lines and primary tumors. Oncogene, 12: 451-455, 1996.
54. Zhang, S. Y., Kleinszanto, A. J. P., Sauter, E. R., Shafarenko, M., Mitsunaga, S., Nobori, T., Carson, D. A., Ridge, J. A., and Goodrow, T. L. Higher frequency of alterations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res., 54: 5050-5053, 1994.
55. Peters, G. The D-type cyclins and their role in tumorigenesis. Cell, 18: 89-96, 1994.
56. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 368: 753-756, 1994.
57. Kamb, A., Gruis, N. A., Weaverfeldhaus, J., Liu, Q. Y., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
58. Mori, T., Miura, K., Aoki, T., Nishihira, T., Shozo, N., and Nakamura, Y. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res., 54: 3396-3397, 1994.
59. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M., and Jones, P. A. Methylation of the 5′CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
60. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
61. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor CDKN2/p16 in human cancers. Nat. Med., 7: 686-692, 1995.
62. Reed, A. L., Califano, J., Cairns, P., Westra, W. H., Jones, R. M., Koch, W., Ahrend, S., Eby, Y., Sewell, D., Nawroz, H., Bartek, J., and Sidransky, D. High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res., 56: 3630-3633, 1996.
63. Nishikawa, R., Furnari, F. B., Lin, H., Arap, W., Berger, M. S., Cavenee, W. K., and Su Hang, H-J. Loss of p16INK4 expression is frequent in high grade gliomas. Cancer Res., 55: 1941-1945, 1995.
64. Schmidt, E. E., Ichimura, K., Reifenberger, G., and Collins, V. P. CDKN2 (p16/MTS1) gene deletions or cdk4 amplification occurs in the majority of glioblastomas. Cancer Res., 54: 6321-6324, 1994.
65. Sonoda, Y., Yoshimoto, T., and Sekiya, T. Homozygous deletion of the MTS1/p16 and MTS2/p15 genes and amplification of the cdk4 gene in glioma. Oncogene, 11: 2145-2149, 1995.
66. Loughran, O., Malliri, A., Owens, D., Gallimore, P. H., Stanley, M. A., Ozanne, B., Frame, M. C., and Parkinson, E. K. Association of CDKN2/ p16ink4A with human head and neck keratinocyte replicative senescence: relationship of dysfunction to immortality and neoplasia. Oncogene, 13: 561-568, 1996.
67. Rheinwald, J. G., and Beckett, M. A. Defective terminal differentiation in culture as a consistent and selectable character of malignant human keratinocytes. Cell, 22: 629-632, 1980.
68. Rheinwald, J. G., and Beckett, M. A. Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultures from human squamous cell carcinomas. Cancer Res., 41: 1657-1663, 1981.
69. Schlegel, R., Phelps, W. C., Zhang, Y-L., and Barbosa, M. Quantitative keratinocyte assay detects two biological activities of human papillomavirus DNA and identifies viral types associated with cervical carcinoma. EMBO J., 7: 3181-3187, 1988.
70. Latham, K. M., Eastman, S. W., Wong, A., and Hinds, P. W. Inhibition of p53-mediated growth arrest by overexpression of cyclin-dependent kinases. Mol. Cell. Biol., 16: 4445-4455, 1996.
71. Hinds, P. W., Mittnacht, S., Dulic, V., Arnold, A., Reed, S. I., and Weinberg, R. A. Regulation of retinoblastoma protein functions by ectopic expression of human cyclins. Cell, 70: 993-1006, 1992.
72. Ausubel, F. M., Brent, R., Kingston, R. E., Moore, D. D., Seidman, J. G., Smith, J. A., and Struhl, K. Short Protocols in Molecular Biology, Ed. 2, pp. 2-4. New York: Greene Publishing Associates and John Wiley & Sons, 1992.
73. DeCaprio, J. A., Ludlow, J. W., Figge, J., Shew, J-Y., Huang, C-M., Lee, W-H., Marsilio, E., Paucho, E., and Livingston, D. M. SV40 large tumor antigen forms a specific complex with the product of the retinoblastoma susceptibility gene. Cell, 54: 275-283, 1988.
74. Wu, E. W., Clemens, K. E., Heck, D. V., and Münger, K. The human papillomavirus E7 oncoprotein and the cellular transcription factor E2F bind to separate sites on the retinoblastoma tumor suppressor protein. J. Virol., 67: 2402-2407, 1993.
75. Tenan, M., Benedetti, S., and Finocchiaro, G. Deletion and transfection analysis of the p15/MTS2 gene in malignant melanomas. Biochem. Biophys. Res. Commun., 217: 195-202, 1995.
76. Zhou, X., Suzuki, H., Shimada, Y., Imamura, M., Yin, J., Jiang, H., Tarmin, L., Abraham, J. M., and Meltzer, S. J. Genomic DNA and messenger RNA expression alterations of the CDKN2B and CDKN2 genes in esophageal squamous carcinoma cell lines. Genes Chromosomes Cancer, 13: 285-290, 1995.
77. Kamb, A., Shattuck-Eidens, D., Eeles, R., Liu, Q., Gruis, N. A., Ding, W., Hussey, C., Tran, T., Miki, Y., Weaver-Feldhaus, J., McClure, M., Aitken, J. F., Anderson, D. E., Bergman, W., Frants, R., Goldgar, D. E., Green, A., MacLennan, R., Martin, N. G., Meyer, L. J., Youl, P., Zone, J. J., Skolnick, M. H., and Cannon-Albright, L. A. Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nat. Genet., 8: 22-26, 1994.